Porton Fine Chemicals Ltd (300363) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Porton Fine Chemicals Ltd (300363) has a cash flow conversion efficiency ratio of 0.023x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥126.55 Million ≈ $18.52 Million USD) by net assets (CN¥5.49 Billion ≈ $803.76 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Porton Fine Chemicals Ltd to measure how much of total assets are equity-financed.
Porton Fine Chemicals Ltd - Cash Flow Conversion Efficiency Trend (2009–2024)
This chart illustrates how Porton Fine Chemicals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Porton Fine Chemicals Ltd cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Porton Fine Chemicals Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Porton Fine Chemicals Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ITMAX System Berhad
KLSE:5309
|
-0.009x |
|
Anhui Shanying Paper Industry Co Ltd
SHG:600567
|
0.050x |
|
Everi Holdings Inc
NYSE:EVRI
|
1.295x |
|
Playtika Holding Corp
NASDAQ:PLTK
|
-1.563x |
|
Hunan Corun New Energy Co Ltd
SHG:600478
|
0.004x |
|
VIA Technologies Inc
TW:2388
|
0.109x |
|
Jinhui Liquor Co Ltd
SHG:603919
|
-0.011x |
|
CVR Partners LP
NYSE:UAN
|
0.243x |
Annual Cash Flow Conversion Efficiency for Porton Fine Chemicals Ltd (2009–2024)
The table below shows the annual cash flow conversion efficiency of Porton Fine Chemicals Ltd from 2009 to 2024. For the full company profile with market capitalisation and key ratios, see Porton Fine Chemicals Ltd (300363) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥5.41 Billion ≈ $791.83 Million |
CN¥405.53 Million ≈ $59.34 Million |
0.075x | -27.33% |
| 2023-12-31 | CN¥6.10 Billion ≈ $892.61 Million |
CN¥629.06 Million ≈ $92.05 Million |
0.103x | -73.97% |
| 2022-12-31 | CN¥6.47 Billion ≈ $947.10 Million |
CN¥2.56 Billion ≈ $375.26 Million |
0.396x | +245.42% |
| 2021-12-31 | CN¥4.19 Billion ≈ $612.56 Million |
CN¥480.17 Million ≈ $70.26 Million |
0.115x | -22.83% |
| 2020-12-31 | CN¥3.39 Billion ≈ $496.54 Million |
CN¥504.37 Million ≈ $73.81 Million |
0.149x | +29.63% |
| 2019-12-31 | CN¥3.06 Billion ≈ $448.41 Million |
CN¥351.37 Million ≈ $51.42 Million |
0.115x | +70.75% |
| 2018-12-31 | CN¥2.88 Billion ≈ $421.91 Million |
CN¥193.62 Million ≈ $28.33 Million |
0.067x | -66.38% |
| 2017-12-31 | CN¥1.45 Billion ≈ $212.07 Million |
CN¥289.46 Million ≈ $42.36 Million |
0.200x | -4.09% |
| 2016-12-31 | CN¥1.37 Billion ≈ $200.49 Million |
CN¥285.33 Million ≈ $41.75 Million |
0.208x | +118.72% |
| 2015-12-31 | CN¥1.18 Billion ≈ $172.60 Million |
CN¥112.31 Million ≈ $16.43 Million |
0.095x | -31.71% |
| 2014-12-31 | CN¥874.42 Million ≈ $127.96 Million |
CN¥121.92 Million ≈ $17.84 Million |
0.139x | -47.62% |
| 2013-12-31 | CN¥428.43 Million ≈ $62.69 Million |
CN¥114.05 Million ≈ $16.69 Million |
0.266x | -23.60% |
| 2012-12-31 | CN¥327.76 Million ≈ $47.96 Million |
CN¥114.21 Million ≈ $16.71 Million |
0.348x | +31.02% |
| 2011-12-31 | CN¥246.01 Million ≈ $36.00 Million |
CN¥65.43 Million ≈ $9.57 Million |
0.266x | +21.40% |
| 2010-12-31 | CN¥163.21 Million ≈ $23.88 Million |
CN¥35.75 Million ≈ $5.23 Million |
0.219x | -44.12% |
| 2009-12-31 | CN¥81.60 Million ≈ $11.94 Million |
CN¥31.99 Million ≈ $4.68 Million |
0.392x | -- |
About Porton Fine Chemicals Ltd
Porton Pharma Solutions Ltd. provides contract development and manufacturing organization (CDMO) solutions for small molecules, tides, biologics, and conjugates from pre-clinical to commercial. It has a strategic collaboration with Aojin Life Sciences to advance XDC conjugate drugs; and strategic partnership with Dragon Sail Pharmaceutical to build a new ecosystem for ADC drug development, produc… Read more